Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Nulibry Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C21306-A

    Molybdenum Cofactor Deficiency (MoCD) Type A — Nulibry (fosdenopterin) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C21306-A alerts

    Get alerted when Policy C21306-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of intravenous Nulibry (fosdenopterin) for members with confirmed or presumptive Molybdenum Cofactor Deficiency Type A. It establishes diagnostic, documentation, prescriber, dosing, continuation, administration-site, and duration-of-approval requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyMolybdenum Cofactor Deficiency (MoCD) Type A — Nulibry (fosdenopterin)
    Policy CodePolicy C21306-A
    Change TypeRevision — no material clinical or coverage change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization with documentation supporting diagnosis, member-specific dosing, baseline assessment, qualified prescriber, and administration requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The revision history identifies notable revisions to quantity, appendix, and coding/billing information in Q3 2026.

    NulibryCovered drug
    3 or 12 monthsInitial authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0.9 mg/kg
    Maximum daily dose
    IV once dailyAdministration
    Ultra-rareDisease classification

    Coverage Criteria

    Initial Therapy

    Initial therapy is covered when ALL of the following are met.

    Initial therapy

    • Diagnostic evidence

      • Genetic diagnosis: Genetic testing confirms MoCD Type A.
      • Presumptive diagnosis: Clinical symptoms began within 28 days of birth, including seizures, exaggerated startle response, high-pitched cry, axial hypotonia, limb hypertonia, or feeding difficulties, AND laboratory signs are consistent with MoCD Type A, including elevated urinary sulfite, S-sulfocysteine, xanthine, and hypoxanthine with low levels of uric acid in the blood and urine.Symptoms within 28 days of birth
    • Member-specific information: The member's current weight in kilograms, gestational age for members under 1 year, and prescribed dose are documented.
    • Baseline assessment: Clinical progress notes assess the member's condition and physical function to establish a baseline for follow-up assessments, including neurological function, gross motor function, and baseline biomarkers such as urinary sulfite or S-sulfocysteine levels.
    • Prescriber qualification: Nulibry is prescribed by or in consultation with a board-certified neonatologist, neurologist, metabolic specialist, or geneticist.

      If prescribed in consultation, consultation notes must be submitted.

    Continuation Therapy

    Continuation therapy is covered when ALL of the following are met.

    Continuation therapy

    • Safety: The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive clinical response

      • Biomarker response: Improvement in baseline biomarkers.
      • Neurological response: Improvement in neurological function.
      • Gross motor response: Improvement in gross motor function.

    Uses of Nulibry (fosdenopterin) other than the covered indication for Molybdenum Cofactor Deficiency Type A are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Coding and Dose Parameters

    Covered HCPCS CodesHCPCSCovered
    J1809Injection, fosdenopterin, 0.1 mg
    Symptom onset
    Required onsetClinical symptoms must begin within 28 days of birth.
    Examples of symptomsSeizures, exaggerated startle response, high-pitched cry, axial hypotonia, limb hypertonia, or feeding difficulties.
    Consistent laboratory findingsElevated urinary sulfite, S-sulfocysteine, xanthine, and hypoxanthine, with low uric acid levels in blood and urine.
    Maximum daily dose
    Maximum daily dose0.9 mg/kg daily.
    Weight basisBased on actual body weight.
    Quantity limit

    Provider Requirements and Decision Risks

    Prior Authorization

    Prior Authorization Required

    Molina requires prior authorization before Nulibry (fosdenopterin) is covered. Submit the request for utilization-management review with complete medical-necessity documentation.

    Documentation Required

    Diagnosis Documentation

    Document the diagnosis pathway supporting MoCD Type A. The submission must establish either genetic confirmation or presumptive diagnosis based on symptom onset within 28 days of birth together with consistent laboratory findings.

    • Genetic testing confirming MoCD Type A; or
    • Clinical symptoms within 28 days of birth, such as seizures, exaggerated startle response, high-pitched cry, axial hypotonia, limb hypertonia, or feeding difficulties, plus elevated urinary sulfite, S-sulfocysteine, xanthine, and hypoxanthine and low blood and urine uric acid.

    Disease Background

    Molybdenum cofactor deficiency is an inherited autosomal recessive metabolic disorder involving deficiency of molybdenum-dependent enzymes. In MoCD Type A, MOSC1 gene mutations impair production of cyclic pyranopterin monophosphate, leading to sulfite accumulation and rapidly progressive neurological injury. Nulibry provides cPMP exogenously and is indicated to reduce the risk of mortality in patients with MoCD Type A.

    Key Definition

    Molybdenum Cofactor Deficiency Type A (MoCD Type A)
    InheritanceAn inherited autosomal recessive metabolic disorder.
    Enzyme deficienciesDeficiency of sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase.
    Type A causeMoCD Type A is caused by MOSC1 gene mutations that impair synthesis of cyclic pyranopterin monophosphate (cPMP).

    Nulibry Initial Therapy

    Nulibry Initial Therapy

    Nulibry initial therapy requires ALL of the following criteria.

    Nulibry initial therapy

    • Documented diagnosis

      • Genetically confirmed diagnosis: Genetic testing confirms MoCD Type A.
      • Presumptive diagnosis: Clinical symptoms began within 28 days of birth, including seizures, exaggerated startle response, high-pitched cry, axial hypotonia, limb hypertonia, or feeding difficulties, AND laboratory signs are consistent with MoCD Type A, including elevated urinary sulfite, S-sulfocysteine, xanthine, and hypoxanthine with low levels of uric acid in the blood and urine.Symptoms within 28 days of birth

    Nulibry Continuation Therapy

    Nulibry Continuation Therapy

    Nulibry continuation therapy requires ALL of the following criteria.

    Nulibry continuation therapy

    • No intolerable adverse effects or toxicity: The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    • Positive clinical response

      • Biomarker improvement: Improvement in baseline biomarkers.
      • Neurological improvement: Improvement in neurological function.

    Weight-Based Dosing and Quantity Limits

    Nulibry (fosdenopterin)—preterm neonates under 1 year
    Initial dose0.4 mg/kg daily.
    Months 1 and 20.7 mg/kg daily.
    Months 3 through 120.9 mg/kg daily.
    Nulibry (fosdenopterin)—term neonates under 1 year
    Initial dose0.55 mg/kg daily.
    Months 1 and 20.75 mg/kg daily.
    Months 3 through 120.9 mg/kg daily.

    Administration Site

    Billing Rule

    Use the recommended hospital outpatient setting

    For administration in a non-inpatient hospital facility-based location, use the pharmacy or medical benefit coverage setting recommended by Molina for infused medications.

    Policy Summary
    PayerMolina Healthcare
    PolicyMolybdenum Cofactor Deficiency (MoCD) Type A — Nulibry (fosdenopterin)
    Policy CodePolicy C21306-A
    Change TypeRevision — no material clinical or coverage change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization with documentation supporting diagnosis, member-specific dosing, baseline assessment, qualified prescriber, and administration requirements.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dose ParametersProvider Requirements and Decision RisksDisease BackgroundKey DefinitionNulibry Initial TherapyNulibry Continuation TherapyWeight-Based Dosing and Quantity LimitsAdministration Site
  1. Developmental response: Achievement of developmental milestones.
  2. Diagnostic confirmation: Genetic confirmation of MoCD Type A is provided if the initial authorization was based on a presumptive diagnosis.

    Nulibry should be discontinued if MoCD Type A is not confirmed by genetic testing.

  3. The maximum quantity limit is 0.9 mg/kg per day.
    Documentation Required

    Weight, Gestational Age, and Dose

    Include member-specific dosing information in the medical-necessity submission, including current weight, gestational age when the member is under 1 year, and the prescribed dose.

    • For preterm neonates under 1 year of age (gestational age less than 37 weeks): 0.4 mg/kg daily initially; 0.7 mg/kg daily during months 1 and 2; and 0.9 mg/kg daily during months 3 through 12.
    Documentation Required

    Baseline Clinical Assessment

    Submit clinical progress notes that establish the member’s baseline condition and physical function for follow-up assessment.

    • Assess, as applicable, neurological function, gross motor function, and baseline biomarkers such as urinary sulfite or S-sulfocysteine.
    Documentation Required

    Continuation Response Documentation

    For reauthorization, document that the member has tolerated therapy without clinically significant toxicity and has demonstrated a positive clinical response.

    • Document improvement in baseline biomarkers, neurological function, gross motor function, or developmental milestones.
    • The prescriber must attest to, or the clinical reviewer must find, no intolerable adverse effects or drug toxicity.
    Documentation Required

    Genetic Confirmation for Reauthorization

    When the initial authorization was based on a presumptive diagnosis, genetic confirmation of MoCD Type A is required for continuation authorization.

    • Genetic confirmation must be submitted with the reauthorization request when it was not available for the initial authorization.
    Documentation Required

    Specialist Consultation Notes

    Nulibry must be prescribed by, or in consultation with, a qualified specialist. If prescribed in consultation, include the consultation documentation with both the initial request and each reauthorization request.

    • Qualified specialists include a board-certified neonatologist, neurologist, metabolic specialist, or geneticist.
    Documentation Required

    Additional Records Upon Request

    Molina may request additional information during coverage determination, quality-improvement, or fraud, waste, and abuse prevention review. Provide requested records to support medical necessity, non-investigational use, provider qualifications, and benefit eligibility.

    • Potentially requested documentation includes patient records, test results, and credentials of the provider ordering or performing the drug or service.
    Denial Risk

    Non-Covered or Investigational Use

    Uses of Nulibry other than the covered MoCD Type A indication are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    • Coverage remains subject to the member’s benefit plan and applicable Molina coverage requirements.
    Denial Risk

    Failure to Confirm Presumptive Diagnosis

    Nulibry should be discontinued if genetic testing does not confirm MoCD Type A when confirmation is required after an initial presumptive authorization.

    • Initial authorization may be limited to 3 months for a presumptive diagnosis; genetically confirmed diagnoses may receive up to 12 months.
    Denial Risk

    Continuation Criteria Not Met

    Reauthorization may be denied when continuation requirements are not met, including intolerable adverse effects or drug toxicity, lack of documented clinical response, or failure to provide required genetic confirmation.

    • Continuation authorization is generally for 12 months when all applicable criteria are satisfied.
    Denial Risk

    Insufficient Medical or Billing Documentation

    Incomplete or unsupported medical or billing documentation may result in reimbursement denial or other action. Molina may deny payment when records do not support medical necessity, non-investigational use, benefit coverage, or appropriate billing practices.

    • Molina may reject or deny claims and recover payments for inappropriate billing or services that are not covered benefits.
    • Providers are responsible for using industry-standard coding practices; listing a code in the policy does not guarantee coverage.
    Member-specific information:
    The member's current weight in kilograms, gestational age for members under 1 year, and prescribed dose are documented.
  4. Baseline assessment: Clinical progress notes assess the member's condition and physical function to establish a baseline for follow-up assessments, including neurological function, gross motor function, and baseline biomarkers such as urinary sulfite or S-sulfocysteine levels.
  5. Qualified prescriber: Nulibry is prescribed by or in consultation with a board-certified neonatologist, neurologist, metabolic specialist, or geneticist.

    If prescribed in consultation, consultation notes must be submitted with the initial request and reauthorization requests.

  6. Gross motor improvement: Improvement in gross motor function.
  7. Developmental progress: Achievement of developmental milestones.
  8. Genetic confirmation when required: Genetic confirmation of MoCD Type A is provided if the initial authorization was based on a presumptive diagnosis.

    Nulibry should be discontinued if MoCD Type A is not confirmed by genetic testing.

  9. Nulibry (fosdenopterin)—members 1 year or older
    Eligible membersMembers 1 year of age or older.
    Daily dose0.9 mg/kg daily.
    Administration frequencyAdminister once daily.
    Nulibry (fosdenopterin)—maximum quantity
    Maximum daily quantity0.9 mg/kg daily.
    Weight basisBased on actual body weight.
    FrequencyThe quantity limit is calculated per day.